Date: July 8 - 11, 2026
Location: Montréal, Canada

ISSCR is where the stem-cell community gathers to share breakthrough science and tackle the translational challenges that stand between discovery and patient impact. This year's theme — Building Bridges from Bench to Bedside — speaks directly to what Cellistic does every day: turning promising iPSC science into robust, scalable processes ready for the clinic.

Whether you're developing an allogeneic cell therapy for solid tumors, engineering next-generation immune effector cells, or advancing a regenerative medicine program, our team is in Montréal to discuss how industrialized iPSC manufacturing can accelerate your timeline and de-risk your path to IND.

 

As a Bronze sponsor, we're proud to support ISSCR's mission of advancing stem-cell sciences and translation.

 

Booth

Booth #: 1404

Stop by our booth in the exhibition hall to:

  • Explore case studies on iPSC-derived immune-cell and regenerative-medicine programs
  • Discuss your specific manufacturing and cell-line development challenges
  • Meet our scientists and business development team one-on-one

 

Spotlight talk

  • Title: Industrialization of iPSC-Derived Allogeneic Cell Therapies: Challenges and Breakthroughs 

  • Speaker: Suzanne Snellenberg, VP Cell Line Development

  • When: Day 2 - 6.30 pm - 7 pm

  • Where: ROOM 513b, LEVEL 5 

Abstract: iPSC-derived allogeneic cell therapies are emerging as a cornerstone of next-generation immuno-oncology and regenerative medicine. In this presentation, our VP of Cell Line Development explores the breakthroughs driving iPSC industrialization — from CRISPR-enabled genome editing and engineered master cell banks to scalable bioprocessing strategies and rigorous quality control frameworks. The session addresses how standardized processes, automation, and tailored differentiation protocols come together to deliver clinical-ready cell therapies that can be deployed globally. 

 

Poster Presentations

We're presenting two abstracts that demonstrate our achievements and commitment to advancing the field:

  1. Accelerating Allogeneic Cell Therapies Through Clinically Compliant iPSC Line Generation

  2. Scalable Generation of iPSC-Derived αβ T Cells Using the Echo™-T Platform

Posters will be available for upload after ISSCR presentations.

 

Why Meet With Cellistic?

For Immune-Cell Therapy Developers
The shift from autologous to allogeneic models promises broader patient access — but it demands an entirely new manufacturing backbone. Cellistic offers a full-platform solution: from reprogramming and gene editing through clonal selection to GMP-ready scalable manufacturing. Whether you're working on CAR-T, TCR, or NK cell therapies, we co-develop the allogeneic platform around your asset and carry it from research through development to GMP.

For iPSC Cell Therapy & Regenerative Medicine Innovators
Your science works at lab scale — the challenge is translating it into reproducible GMP manufacturing while managing process complexity and the shortage of iPSC-specialist CDMOs. Cellistic steps in post proof-of-concept for process development, scale-up, and GMP manufacturing of drug substance and drug product — bringing specialist industrialization expertise to your program.

 

Meet the team

Book time with our team in Montréal